Amgen (AMGN) Assets (2009 - 2026)
Amgen's quarterly Assets came in at $92.5 billion in Q1 2026, up 3.51% year-on-year from $89.4 billion in Q1 2025, and up 2.12% quarter-over-quarter from $90.6 billion in Q4 2025.
Amgen has reported Assets for 18 years, with the latest figure at $92.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Assets rose 3.51% year-over-year to $92.5 billion; the trailing twelve-month figure through Mar 2026 stood at $92.5 billion (up 3.51% YoY), and the FY2025 full-year result was $90.6 billion, down 1.36% from the prior year.
- Assets for Q1 2026 stood at $92.5 billion, up from $90.6 billion in the prior quarter.
- The five-year high for Assets was $97.2 billion in Q4 2023, with the low at $59.2 billion in Q1 2022.
- Average Assets over 5 years is $84.2 billion, with a median of $90.3 billion recorded in 2023.
- Year-over-year, Assets surged 52.24% in 2023 and decreased 5.47% in 2024.
- Tracing AMGN's Assets over 5 years: stood at $65.1 billion in 2022, then soared by 49.19% to $97.2 billion in 2023, then fell by 5.47% to $91.8 billion in 2024, then retreated by 1.36% to $90.6 billion in 2025, then rose by 2.12% to $92.5 billion in 2026.
- The last three Assets figures came in at $92.5 billion (Q1 2026), $90.6 billion (Q4 2025), and $90.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 116.58 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 200.89 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 136.46 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 128.69 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 92.50 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 56.28 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 208.00 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 86.48 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 81.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.50 Bn |
| Dec 31, 2025 | 90.59 Bn |
| Sep 30, 2025 | 90.14 Bn |
| Jun 30, 2025 | 87.90 Bn |
| Mar 31, 2025 | 89.37 Bn |
| Dec 31, 2024 | 91.84 Bn |
| Sep 30, 2024 | 90.88 Bn |
| Jun 30, 2024 | 90.91 Bn |
| Mar 31, 2024 | 92.98 Bn |
| Dec 31, 2023 | 97.15 Bn |
| Sep 30, 2023 | 90.53 Bn |
| Jun 30, 2023 | 90.27 Bn |
| Mar 31, 2023 | 88.72 Bn |
| Dec 31, 2022 | 65.12 Bn |
| Sep 30, 2022 | 63.70 Bn |
| Jun 30, 2022 | 59.29 Bn |
| Mar 31, 2022 | 59.20 Bn |
| Dec 31, 2021 | 61.17 Bn |
| Sep 30, 2021 | 64.99 Bn |
| Jun 30, 2021 | 59.77 Bn |
| Mar 31, 2021 | 62.54 Bn |
| Dec 31, 2020 | 62.95 Bn |
| Sep 30, 2020 | 64.64 Bn |
| Jun 30, 2020 | 65.01 Bn |
| Mar 31, 2020 | 61.67 Bn |
| Dec 31, 2019 | 59.71 Bn |
| Sep 30, 2019 | 59.54 Bn |
| Jun 30, 2019 | 59.37 Bn |
| Mar 31, 2019 | 64.00 Bn |
| Dec 31, 2018 | 66.42 Bn |
| Sep 30, 2018 | 67.33 Bn |
| Jun 30, 2018 | 67.68 Bn |
| Mar 31, 2018 | 71.16 Bn |
| Dec 31, 2017 | 79.95 Bn |
| Sep 30, 2017 | 80.33 Bn |
| Jun 30, 2017 | 79.59 Bn |
| Mar 31, 2017 | 77.86 Bn |
| Dec 31, 2016 | 77.63 Bn |
| Sep 30, 2016 | 78.15 Bn |
| Jun 30, 2016 | 75.47 Bn |
| Mar 31, 2016 | 75.12 Bn |
| Dec 31, 2015 | 71.45 Bn |
| Sep 30, 2015 | 71.87 Bn |
| Jun 30, 2015 | 71.21 Bn |
| Mar 31, 2015 | 68.95 Bn |
| Dec 31, 2014 | 69.01 Bn |
| Sep 30, 2014 | 70.78 Bn |
| Jun 30, 2014 | 69.53 Bn |
| Mar 31, 2014 | 67.00 Bn |
| Dec 31, 2013 | 66.13 Bn |
| Sep 30, 2013 | 57.07 Bn |
| Jun 30, 2013 | 52.61 Bn |
| Mar 31, 2013 | 51.64 Bn |
| Dec 31, 2012 | 54.30 Bn |
| Sep 30, 2012 | 55.45 Bn |
| Dec 31, 2011 | 48.87 Bn |
| Mar 31, 2010 | 40.37 Bn |
| Dec 31, 2009 | 39.63 Bn |
| Sep 30, 2009 | 40.94 Bn |
| Jun 30, 2009 | 38.84 Bn |